Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota
CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile , inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. CRS3123 is a novel small molecule t...
Saved in:
| Published in | Antimicrobial agents and chemotherapy Vol. 64; no. 1 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
20.12.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0066-4804 1098-6596 1070-6283 1098-6596 |
| DOI | 10.1128/AAC.01395-19 |
Cover
| Abstract | CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of
Clostridioides difficile
, inhibiting
C. difficile
toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial.
CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of
Clostridioides difficile
, inhibiting
C. difficile
toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC
90
value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including
Bacteroides
, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.) |
|---|---|
| AbstractList | CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of
, inhibiting
toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC
value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including
, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.). CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC90 value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including Bacteroides, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.).CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC90 value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including Bacteroides, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.). CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile , inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile , inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC 90 value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including Bacteroides , bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.) CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC90 value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including Bacteroides, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.) CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial. Thirty healthy subjects, ages 18 to 45 years, were randomized into three cohorts of 10 subjects each, receiving either 200, 400, or 600 mg of CRS3123 (8 subjects per cohort) or placebo (2 subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated, with no serious adverse events (SAEs) or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital sign, or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other electrocardiogram (ECG) intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC90 value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after 10 days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes, including Bacteroides, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.) |
| Author | Lomeli, Barbara K. Schettler, Jared Evans, Ronald J. Osborn, Blaire Lozupone, Catherine A. Galbraith, Hal Bell, Stacie J. Ravel, Jacques Jarvis, Thale C. El-Amin, Wael Baqar, Shahida Janjic, Nebojsa Saviolakis, George A. Hazleton, Keith Ochsner, Urs A. |
| Author_xml | – sequence: 1 givenname: Barbara K. surname: Lomeli fullname: Lomeli, Barbara K. organization: Quintiles Phase One Services, Overland Park, Kansas, USA – sequence: 2 givenname: Hal surname: Galbraith fullname: Galbraith, Hal organization: Quintiles Phase One Services, Overland Park, Kansas, USA – sequence: 3 givenname: Jared surname: Schettler fullname: Schettler, Jared organization: Quintiles Phase One Services, Overland Park, Kansas, USA – sequence: 4 givenname: George A. surname: Saviolakis fullname: Saviolakis, George A. organization: DynPort Vaccine Company LLC, Frederick, Maryland, USA – sequence: 5 givenname: Wael surname: El-Amin fullname: El-Amin, Wael organization: DynPort Vaccine Company LLC, Frederick, Maryland, USA – sequence: 6 givenname: Blaire surname: Osborn fullname: Osborn, Blaire organization: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA – sequence: 7 givenname: Jacques orcidid: 0000-0002-0851-2233 surname: Ravel fullname: Ravel, Jacques organization: Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA – sequence: 8 givenname: Keith surname: Hazleton fullname: Hazleton, Keith organization: Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA – sequence: 9 givenname: Catherine A. surname: Lozupone fullname: Lozupone, Catherine A. organization: Division of Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA – sequence: 10 givenname: Ronald J. surname: Evans fullname: Evans, Ronald J. organization: Crestone, Inc., Boulder, Colorado, USA – sequence: 11 givenname: Stacie J. surname: Bell fullname: Bell, Stacie J. organization: Crestone, Inc., Boulder, Colorado, USA – sequence: 12 givenname: Urs A. surname: Ochsner fullname: Ochsner, Urs A. organization: Crestone, Inc., Boulder, Colorado, USA – sequence: 13 givenname: Thale C. surname: Jarvis fullname: Jarvis, Thale C. organization: Crestone, Inc., Boulder, Colorado, USA – sequence: 14 givenname: Shahida surname: Baqar fullname: Baqar, Shahida organization: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA – sequence: 15 givenname: Nebojsa surname: Janjic fullname: Janjic, Nebojsa organization: Crestone, Inc., Boulder, Colorado, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31685472$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUsFu1DAQtVAR3RZunJGPIDXFdhInviBFKS1IbUHs3i0ncXZdHDu1HVb7YfxfHbaUUrjYGvu9mTdv5ggcGGskAK8xOsWYlO-rqj5FOGV5gtkzsMCIlQnNGT0AC4QoTbISZYfgyPsbFOOcoRfgMMW0zLOCLMDPq0kHNWqZVL6VplNmnZxZL-HXjYgnhrVWRrVCw2WYuh20PQwbCZeil2F3AldWSycapdUcCdPNPDeI1n5XRgbV-plRf1ummKQRAK-Fc3abLEfZBjcNsFpLE-BWhQ28ioWGWOhMeTeNQVkzc6-tmx8vphABrbONskG8BM97ob18dX8fg9X5x1X9Kbn8cvG5ri4TkeEyJKygsi9YQ1gmGWoooYR1RdqhjuQ0LRqR91mRU9niIiciixySk7JrWd80eRR8DJJ92smMYrcVWvPRRY1uxzHis_tciJb_cp9jFvEf9vhxagbZRT-DE384Vij-949RG762P3iBy4KSIiZ4e5_A2dtJ-sAHFceitTDSTp6TaCMpMU5nbe_2UOEHwm_s5Ex04kFX3IrHut481vUg6PcaRMDJHhAN9t7J_p8-n-QjT-CtCmKeWOxK6f-T7gC3oNKp |
| CitedBy_id | crossref_primary_10_1002_bmc_5862 crossref_primary_10_1177_08971900241248883 crossref_primary_10_2147_JEP_S242959 crossref_primary_10_1016_j_ijbiomac_2024_131018 crossref_primary_10_3390_biomedicines11020426 crossref_primary_10_1002_anie_202414325 crossref_primary_10_1038_s41429_023_00629_8 crossref_primary_10_1053_j_gastro_2024_10_032 crossref_primary_10_1097_MOG_0000000000000696 crossref_primary_10_3390_biom10121625 crossref_primary_10_3390_antibiotics14030221 crossref_primary_10_1021_acsinfecdis_4c00218 crossref_primary_10_3390_ijms22041750 crossref_primary_10_3389_fmed_2023_1323344 crossref_primary_10_1002_ange_202414325 crossref_primary_10_1007_s11908_020_00730_1 crossref_primary_10_1016_j_ejmech_2024_116303 crossref_primary_10_1128_msystems_01159_21 crossref_primary_10_1016_j_ejmech_2023_115413 crossref_primary_10_22144_ctu_jen_2022_021 |
| Cites_doi | 10.1080/17512433.2017.1362978 10.1086/430315 10.1016/j.cmi.2014.08.017 10.1093/cid/cix1085 10.1186/2049-2618-2-6 10.1111/j.1365-2362.2012.02659.x 10.1056/NEJMoa1602615 10.1093/jac/dkp041 10.1093/bioinformatics/bts611 10.1093/bioinformatics/btr381 10.1056/NEJMoa0910812 10.1056/NEJMc1405194 10.1056/NEJMoa1408913 10.1093/cid/ciu313 10.2174/0929867323666161028162018 10.1016/j.ajic.2014.12.020 10.1093/jac/dkp037 10.1086/651706 10.1093/cid/cis338 10.1016/j.medmal.2017.10.007 10.1111/1469-0691.12418 10.1038/nature19799 10.1111/j.1365-2362.2012.02660.x 10.1038/nmicrobiol.2016.30 10.1126/science.aar1999 10.1128/AAC.02176-12 10.7326/M16-2733 10.1093/jac/dku261 10.1128/AEM.01996-06 10.1038/nmeth.f.303 10.1128/JB.00445-10 10.1086/678428 10.1128/AEM.00062-07 10.1097/QCO.0000000000000320 10.1093/jac/dkp042 10.1128/aac.37.1.32 10.1128/AAC.03774-14 10.1016/S1473-3099(17)30235-9 10.1128/AAC.02760-16 10.1097/TA.0000000000001195 10.1016/S1473-3099(11)70374-7 10.1016/j.mib.2018.07.003 10.1086/592257 10.1186/1757-4749-5-23 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Lomeli et al. Copyright © 2019 Lomeli et al. 2019 Lomeli et al. |
| Copyright_xml | – notice: Copyright © 2019 Lomeli et al. – notice: Copyright © 2019 Lomeli et al. 2019 Lomeli et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY |
| DOI | 10.1128/AAC.01395-19 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | CRS3123 Multiple-Ascending-Dose Phase 1 Clinical Study, Lomeli et al CRS3123 Multiple-Ascending-Dose Phase 1 Clinical Study |
| EISSN | 1098-6596 |
| ExternalDocumentID | 10.1128/aac.01395-19 PMC7187627 01395-19 31685472 10_1128_AAC_01395_19 |
| Genre | Clinical Trial, Phase I Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: HHSN272200800026C – fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: HHSN272200800026C funderid: https://doi.org/10.13039/100000060 – fundername: ; grantid: HHSN272200800026C |
| GroupedDBID | --- .55 0R~ 23M 2WC 39C 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 K-O KQ8 L7B LSO O9- OK1 P2P RHI RNS RPM RSF TR2 UHB W2D W8F WH7 WOQ X7M AGVNZ CGR CUY CVF ECM EIF NPM - 0R 55 AAPBV ABFLS ADACO BXI HZ RHF ZA5 7X8 5PM .GJ 3O- ADTOC AGNAY AI. C1A J5H MVM NEJ UNPAY VH1 WHG X7N XOL Y6R ZGI ZXP ~A~ |
| ID | FETCH-LOGICAL-a418t-976ef79b294e90b62629d73d0d25637ba5f4756ec1752a44182528dc9fbb5123 |
| IEDL.DBID | UNPAY |
| ISSN | 0066-4804 1098-6596 1070-6283 |
| IngestDate | Sun Oct 26 03:51:45 EDT 2025 Tue Sep 30 16:57:47 EDT 2025 Fri Sep 05 06:58:39 EDT 2025 Tue Dec 28 13:59:10 EST 2021 Mon Jul 21 06:00:00 EDT 2025 Wed Oct 01 04:50:42 EDT 2025 Thu Apr 24 22:59:07 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | antibiotic narrow spectrum phase 1 MAD study Clostridioides difficile CRS3123 microbiome gut microbiota sporulation toxin production |
| Language | English |
| License | Copyright © 2019 Lomeli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a418t-976ef79b294e90b62629d73d0d25637ba5f4756ec1752a44182528dc9fbb5123 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Citation Lomeli BK, Galbraith H, Schettler J, Saviolakis GA, El-Amin W, Osborn B, Ravel J, Hazleton K, Lozupone CA, Evans RJ, Bell SJ, Ochsner UA, Jarvis TC, Baqar S, Janjic N. 2020. Multiple-ascending-dose phase 1 clinical study of the safety, tolerability, and pharmacokinetics of CRS3123, a narrow-spectrum agent with minimal disruption of normal gut microbiota. Antimicrob Agents Chemother 64:e01395-19. https://doi.org/10.1128/AAC.01395-19. |
| ORCID | 0000-0002-0851-2233 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://aac.asm.org/content/aac/64/1/e01395-19.full.pdf |
| PMID | 31685472 |
| PQID | 2312281132 |
| PQPubID | 23479 |
| PageCount | 17 |
| ParticipantIDs | unpaywall_primary_10_1128_aac_01395_19 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7187627 proquest_miscellaneous_2312281132 asm2_journals_10_1128_AAC_01395_19 pubmed_primary_31685472 crossref_primary_10_1128_AAC_01395_19 crossref_citationtrail_10_1128_AAC_01395_19 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20191220 |
| PublicationDateYYYYMMDD | 2019-12-20 |
| PublicationDate_xml | – month: 12 year: 2019 text: 20191220 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAbbrev | Antimicrob Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2019 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 Meyers S (e_1_3_3_29_2) 2018; 67 e_1_3_3_38_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 Mercier C (e_1_3_3_48_2) 2013 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 Tablan OC (e_1_3_3_21_2) 1995; 44 e_1_3_3_40_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_49_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_3_2 e_1_3_3_42_2 Vickers, RJ, Tillotson, GS, Nathan, R, Hazan, S, Pullman, J, Lucasti, C, Deck, K, Yacyshyn, B, Maliakkal, B, Pesant, Y, Tejura, B, Roblin, D, Gerding, DN, Wilcox, MH (B37) 2017; 17 Manthey, CF, Eckmann, L, Fuhrmann, V (B13) 2017; 10 Louie, TJ, Miller, MA, Mullane, KM, Weiss, K, Lentnek, A, Golan, Y, Gorbach, S, Sears, P, Shue, YK (B26) 2011; 364 Nayak, SU, Griffiss, JM, Blumer, J, O’Riordan, MA, Gray, W, McKenzie, R, Jurao, RA, An, AT, Le, M, Bell, SJ, Ochsner, UA, Jarvis, TC, Janjic, N, Zenilman, JM (B32) 2017; 61 Lozupone, CA, Hamady, M, Kelley, ST, Knight, R (B48) 2007; 73 Caporaso, JG, Kuczynski, J, Stombaugh, J, Bittinger, K, Bushman, FD, Costello, EK, Fierer, N, Pena, AG, Goodrich, JK, Gordon, JI, Huttley, GA, Kelley, ST, Knights, D, Koenig, JE, Ley, RE, Lozupone, CA, McDonald, D, Muegge, BD, Pirrung, M, Reeder, J, Sevinsky, JR, Turnbaugh, PJ, Walters, WA, Widmann, J, Yatsunenko, T, Zaneveld, J, Knight, R (B43) 2010; 7 Edgar, RC, Haas, BJ, Clemente, JC, Quince, C, Knight, R (B44) 2011; 27 Olsen, MA, Yan, Y, Reske, KA, Zilberberg, MD, Dubberke, ER (B19) 2015; 21 Olsen, MA, Yan, Y, Reske, KA, Zilberberg, M, Dubberke, ER (B18) 2015; 43 Wilcox, MH, Gerding, DN, Poxton, IR, Kelly, C, Nathan, R, Birch, T, Cornely, OA, Rahav, G, Bouza, E, Lee, C, Jenkin, G, Jensen, W, Kim, YS, Yoshida, J, Gabryelski, L, Pedley, A, Eves, K, Tipping, R, Guris, D, Kartsonis, N, Dorr, MB (B7) 2017; 376 Lozupone, CA (B39) 2016; 1 Lessa, FC, Mu, Y, Bamberg, WM, Beldavs, ZG, Dumyati, GK, Dunn, JR, Farley, MM, Holzbauer, SM, Meek, JI, Phipps, EC, Wilson, LE, Winston, LG, Cohen, JA, Limbago, BM, Fridkin, SK, Gerding, DN, McDonald, LC (B4) 2015; 372 Lopetuso, LR, Scaldaferri, F, Petito, V, Gasbarrini, A (B38) 2013; 5 Johnson, S, Louie, TJ, Gerding, DN, Cornely, OA, Chasan-Taber, S, Fitts, D, Gelone, SP, Broom, C, Davidson, DM (B23) 2014; 59 O’Dwyer, K, Spivak, AT, Ingraham, K, Min, S, Holmes, DJ, Jakielaszek, C, Rittenhouse, S, Kwan, AL, Livi, GP, Sathe, G, Thomas, E, Van Horn, S, Miller, LA, Twynholm, M, Tomayko, J, Dalessandro, M, Caltabiano, M, Scangarella-Oman, NE, Brown, JR (B34) 2015; 59 Fadrosh, DW, Ma, B, Gajer, P, Sengamalay, N, Ott, S, Brotman, RM, Ravel, J (B40) 2014; 2 Magill, SS, Edwards, JR, Fridkin, SK (B3) 2014; 370 Debast, SB, Bauer, MP, Kuijper, EJ (B22) 2014; 20 Louie, TJ, Cannon, K, Byrne, B, Emery, J, Ward, L, Eyben, M, Krulicki, W (B36) 2012; 55 Ochsner, UA, Bell, SJ, O’Leary, AL, Hoang, T, Stone, KC, Young, CL, Critchley, IA, Janjic, N (B30) 2009; 63 Goorhuis, A, Bakker, D, Corver, J, Debast, SB, Harmanus, C, Notermans, DW, Bergwerff, AA, Dekker, FW, Kuijper, EJ (B10) 2008; 47 Mercier, C, Boyer, F, Bonin, A, Coissac, E (B47) 2013 Tao, L, Zhang, J, Meraner, P, Tovaglieri, A, Wu, X, Gerhard, R, Zhang, X, Stallcup, WB, Miao, J, He, X, Hurdle, JG, Breault, DT, Brass, AL, Dong, M (B6) 2016; 538 Petrosillo, N (B15) 2018; 48 Tablan, OC, Tenover, FC, Martone, WJ, Gaynes, RP, Jarvis, WR, Favero, MS, Shaw, J (B20) 1995; 44 McDonald, LC, Gerding, DN, Johnson, S, Bakken, JS, Carroll, KC, Coffin, SE, Dubberke, ER, Garey, KW, Gould, CV, Kelly, C, Loo, V, Shaklee Sammons, J, Sandora, TJ, Wilcox, MH (B1) 2018; 66 Merrigan, M, Venugopal, A, Mallozzi, M, Roxas, B, Viswanathan, VK, Johnson, S, Gerding, DN, Vedantam, G (B11) 2010; 192 Ma, GK, Brensinger, CM, Wu, Q, Lewis, JD (B17) 2017; 167 Martin, J, Wilcox, M (B14) 2016; 29 Chapman, BC, Moore, HB, Overbey, DM, Morton, AP, Harnke, B, Gerich, ME, Vogel, JD (B27) 2016; 81 Meyers, S, Shih, J, Neher, JO, Safranek, S (B28) 2018; 67 Brown, KA, Khanafer, N, Daneman, N, Fisman, DN (B8) 2013; 57 Wang, Q, Garrity, GM, Tiedje, JM, Cole, JR (B45) 2007; 73 Kriss, M, Hazleton, KZ, Nusbacher, NM, Martin, CG, Lozupone, CA (B35) 2018; 44 Pepin, J, Alary, ME, Valiquette, L, Raiche, E, Ruel, J, Fulop, K, Godin, D, Bourassa, C (B24) 2005; 40 Critchley, IA, Green, LS, Young, CL, Bullard, JM, Evans, RJ, Price, M, Jarvis, TC, Guiles, JW, Janjic, N, Ochsner, UA (B29) 2009; 63 B2 Gilbart, J, Perry, CR, Slocombe, B (B33) 1993; 37 Dubberke, ER, Schaefer, E, Reske, KA, Zilberberg, M, Hollenbeak, CS, Olsen, MA (B16) 2014; 35 Citron, DM, Warren, YA, Tyrrell, KL, Merriam, V, Goldstein, EJ (B31) 2009; 63 Cornely, OA, Nathwani, D, Ivanescu, C, Odufowora-Sita, O, Retsa, P, Odeyemi, IA (B12) 2014; 69 Chen, P, Tao, L, Wang, T, Zhang, J, He, A, Lam, KH, Liu, Z, He, X, Perry, K, Dong, M, Jin, R (B5) 2018; 360 Flores, R, Shi, J, Gail, MH, Gajer, P, Ravel, J, Goedert, JJ (B41) 2012; 42 Flores, R, Shi, J, Gail, MH, Ravel, J, Goedert, JJ (B42) 2012; 42 Cohen, SH, Gerding, DN, Johnson, S, Kelly, CP, Loo, VG, McDonald, LC, Pepin, J, Wilcox, MH (B21) 2010; 31 Cornely, OA, Crook, DW, Esposito, R, Poirier, A, Somero, MS, Weiss, K, Sears, P, Gorbach, S (B25) 2012; 12 Peretz, A, Shlomo, IB, Nitzan, O, Bonavina, L, Schaffer, PM, Schaffer, M (B9) 2016; 23 Kopylova, E, Noe, L, Touzet, H (B46) 2012; 28 |
| References_xml | – ident: e_1_3_3_14_2 doi: 10.1080/17512433.2017.1362978 – ident: e_1_3_3_25_2 doi: 10.1086/430315 – ident: e_1_3_3_20_2 doi: 10.1016/j.cmi.2014.08.017 – ident: e_1_3_3_2_2 doi: 10.1093/cid/cix1085 – ident: e_1_3_3_41_2 doi: 10.1186/2049-2618-2-6 – ident: e_1_3_3_42_2 doi: 10.1111/j.1365-2362.2012.02659.x – ident: e_1_3_3_8_2 doi: 10.1056/NEJMoa1602615 – ident: e_1_3_3_3_2 – ident: e_1_3_3_30_2 doi: 10.1093/jac/dkp041 – ident: e_1_3_3_47_2 doi: 10.1093/bioinformatics/bts611 – ident: e_1_3_3_45_2 doi: 10.1093/bioinformatics/btr381 – ident: e_1_3_3_27_2 doi: 10.1056/NEJMoa0910812 – ident: e_1_3_3_4_2 doi: 10.1056/NEJMc1405194 – ident: e_1_3_3_5_2 doi: 10.1056/NEJMoa1408913 – ident: e_1_3_3_24_2 doi: 10.1093/cid/ciu313 – ident: e_1_3_3_10_2 doi: 10.2174/0929867323666161028162018 – ident: e_1_3_3_19_2 doi: 10.1016/j.ajic.2014.12.020 – ident: e_1_3_3_32_2 doi: 10.1093/jac/dkp037 – ident: e_1_3_3_22_2 doi: 10.1086/651706 – ident: e_1_3_3_37_2 doi: 10.1093/cid/cis338 – ident: e_1_3_3_16_2 doi: 10.1016/j.medmal.2017.10.007 – ident: e_1_3_3_23_2 doi: 10.1111/1469-0691.12418 – ident: e_1_3_3_7_2 doi: 10.1038/nature19799 – ident: e_1_3_3_43_2 doi: 10.1111/j.1365-2362.2012.02660.x – volume: 67 start-page: 386 year: 2018 ident: e_1_3_3_29_2 article-title: Clinical inquiries: how effective and safe is fecal microbial transplant in preventing C difficile recurrence? publication-title: J Fam Pract – ident: e_1_3_3_40_2 doi: 10.1038/nmicrobiol.2016.30 – ident: e_1_3_3_6_2 doi: 10.1126/science.aar1999 – start-page: 27 volume-title: Programs Abstr SeqBio year: 2013 ident: e_1_3_3_48_2 – ident: e_1_3_3_9_2 doi: 10.1128/AAC.02176-12 – ident: e_1_3_3_18_2 doi: 10.7326/M16-2733 – ident: e_1_3_3_13_2 doi: 10.1093/jac/dku261 – ident: e_1_3_3_49_2 doi: 10.1128/AEM.01996-06 – ident: e_1_3_3_44_2 doi: 10.1038/nmeth.f.303 – ident: e_1_3_3_12_2 doi: 10.1128/JB.00445-10 – ident: e_1_3_3_17_2 doi: 10.1086/678428 – ident: e_1_3_3_46_2 doi: 10.1128/AEM.00062-07 – ident: e_1_3_3_15_2 doi: 10.1097/QCO.0000000000000320 – ident: e_1_3_3_31_2 doi: 10.1093/jac/dkp042 – ident: e_1_3_3_34_2 doi: 10.1128/aac.37.1.32 – ident: e_1_3_3_35_2 doi: 10.1128/AAC.03774-14 – ident: e_1_3_3_38_2 doi: 10.1016/S1473-3099(17)30235-9 – ident: e_1_3_3_33_2 doi: 10.1128/AAC.02760-16 – ident: e_1_3_3_28_2 doi: 10.1097/TA.0000000000001195 – ident: e_1_3_3_26_2 doi: 10.1016/S1473-3099(11)70374-7 – ident: e_1_3_3_36_2 doi: 10.1016/j.mib.2018.07.003 – ident: e_1_3_3_11_2 doi: 10.1086/592257 – ident: e_1_3_3_39_2 doi: 10.1186/1757-4749-5-23 – volume: 44 start-page: 1 issue: 12 year: 1995 ident: e_1_3_3_21_2 article-title: Recommendations for preventing the spread of vancomycin resistance publication-title: MMWR Recommend Rep – volume: 35 start-page: 1400 year: 2014 end-page: 1407 ident: B16 article-title: Attributable inpatient costs of recurrent Clostridium difficile infections publication-title: Infect Control Hosp Epidemiol doi: 10.1086/678428 – volume: 20 start-page: 1 year: 2014 end-page: 26 ident: B22 article-title: European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12418 – volume: 17 start-page: 735 year: 2017 end-page: 744 ident: B37 article-title: Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30235-9 – volume: 40 start-page: 1591 year: 2005 end-page: 1597 ident: B24 article-title: Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada publication-title: Clin Infect Dis doi: 10.1086/430315 – volume: 42 start-page: 848 year: 2012 end-page: 854 ident: B42 article-title: Assessment of the human faecal microbiota: I. Measurement and reproducibility of selected enzymatic activities publication-title: Eur J Clin Invest doi: 10.1111/j.1365-2362.2012.02660.x – volume: 538 start-page: 350 year: 2016 end-page: 355 ident: B6 article-title: Frizzled proteins are colonic epithelial receptors for C. difficile toxin B publication-title: Nature doi: 10.1038/nature19799 – volume: 47 start-page: 1162 year: 2008 end-page: 1170 ident: B10 article-title: Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078 publication-title: Clin Infect Dis doi: 10.1086/592257 – volume: 63 start-page: 972 year: 2009 end-page: 976 ident: B31 article-title: Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkp037 – volume: 21 start-page: 164 year: 2015 end-page: 170 ident: B19 article-title: Recurrent Clostridium difficile infection is associated with increased mortality publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2014.08.017 – volume: 28 start-page: 3211 year: 2012 end-page: 3217 ident: B46 article-title: SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts611 – volume: 73 start-page: 1576 year: 2007 end-page: 1585 ident: B48 article-title: Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities publication-title: Appl Environ Microbiol doi: 10.1128/AEM.01996-06 – volume: 37 start-page: 32 year: 1993 end-page: 38 ident: B33 article-title: High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases publication-title: Antimicrob Agents Chemother doi: 10.1128/aac.37.1.32 – volume: 63 start-page: 954 year: 2009 end-page: 963 ident: B29 article-title: Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkp041 – volume: 59 start-page: 289 year: 2015 end-page: 298 ident: B34 article-title: Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.03774-14 – volume: 10 start-page: 1239 year: 2017 end-page: 1250 ident: B13 article-title: Therapy for Clostridium difficile infection—any news beyond metronidazole and vancomycin? publication-title: Expert Rev Clin Pharmacol doi: 10.1080/17512433.2017.1362978 – volume: 67 start-page: 386 year: 2018 end-page: 388 ident: B28 article-title: Clinical inquiries: how effective and safe is fecal microbial transplant in preventing C difficile recurrence? publication-title: J Fam Pract – volume: 43 start-page: 318 year: 2015 end-page: 322 ident: B18 article-title: Impact of Clostridium difficile recurrence on hospital readmissions publication-title: Am J Infect Control doi: 10.1016/j.ajic.2014.12.020 – volume: 81 start-page: 756 year: 2016 end-page: 764 ident: B27 article-title: Fecal microbiota transplant in patients with Clostridium difficile infection: a systematic review publication-title: J Trauma Acute Care Surg doi: 10.1097/TA.0000000000001195 – volume: 364 start-page: 422 year: 2011 end-page: 431 ident: B26 article-title: Fidaxomicin versus vancomycin for Clostridium difficile infection publication-title: N Engl J Med doi: 10.1056/NEJMoa0910812 – volume: 42 start-page: 855 year: 2012 end-page: 863 ident: B41 article-title: Assessment of the human faecal microbiota: II. Reproducibility and associations of 16S rRNA pyrosequences publication-title: Eur J Clin Invest doi: 10.1111/j.1365-2362.2012.02659.x – volume: 7 start-page: 335 year: 2010 end-page: 336 ident: B43 article-title: QIIME allows analysis of high-throughput community sequencing data publication-title: Nat Methods doi: 10.1038/nmeth.f.303 – ident: B2 article-title: CDC . 2015 . Nearly half a million Americans suffered from Clostridium difficile infections in a single year . https://www.cdc.gov/media/releases/2015/p0225-clostridium-difficile.html . – volume: 5 start-page: 23 year: 2013 ident: B38 article-title: Commensal clostridia: leading players in the maintenance of gut homeostasis publication-title: Gut Pathog doi: 10.1186/1757-4749-5-23 – volume: 66 start-page: e1 year: 2018 end-page: e48 ident: B1 article-title: Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) publication-title: Clin Infect Dis doi: 10.1093/cid/cix1085 – volume: 370 start-page: 2542 year: 2014 end-page: 2543 ident: B3 article-title: Survey of health care-associated infections publication-title: N Engl J Med doi: 10.1056/NEJMc1405194 – volume: 360 start-page: 664 year: 2018 end-page: 669 ident: B5 article-title: Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B publication-title: Science doi: 10.1126/science.aar1999 – volume: 61 year: 2017 ident: B32 article-title: Safety, tolerability, systemic exposure, and metabolism of CRS3123, a methionyl-tRNA synthetase inhibitor developed for treatment of Clostridium difficile, in a phase 1 study publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02760-16 – volume: 167 start-page: 152 year: 2017 end-page: 158 ident: B17 article-title: Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study publication-title: Ann Intern Med doi: 10.7326/M16-2733 – volume: 44 start-page: 1 issue: (RR-12) year: 1995 end-page: 13 ident: B20 article-title: Recommendations for preventing the spread of vancomycin resistance publication-title: MMWR Recommend Rep – volume: 69 start-page: 2892 year: 2014 end-page: 2900 ident: B12 article-title: Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison publication-title: J Antimicrob Chemother doi: 10.1093/jac/dku261 – volume: 12 start-page: 281 year: 2012 end-page: 289 ident: B25 article-title: Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70374-7 – volume: 63 start-page: 964 year: 2009 end-page: 971 ident: B30 article-title: Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkp042 – volume: 55 start-page: S132 year: 2012 end-page: S142 ident: B36 article-title: Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI publication-title: Clin Infect Dis doi: 10.1093/cid/cis338 – volume: 372 start-page: 825 year: 2015 end-page: 834 ident: B4 article-title: Burden of Clostridium difficile infection in the United States publication-title: N Engl J Med doi: 10.1056/NEJMoa1408913 – volume: 376 start-page: 305 year: 2017 end-page: 317 ident: B7 article-title: Bezlotoxumab for prevention of recurrent Clostridium difficile infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1602615 – volume: 57 start-page: 2326 year: 2013 end-page: 2332 ident: B8 article-title: Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02176-12 – volume: 31 start-page: 431 year: 2010 end-page: 455 ident: B21 article-title: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) publication-title: Infect Control Hosp Epidemiol doi: 10.1086/651706 – volume: 73 start-page: 5261 year: 2007 end-page: 5267 ident: B45 article-title: Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy publication-title: Appl Environ Microbiol doi: 10.1128/AEM.00062-07 – volume: 48 start-page: 18 year: 2018 end-page: 22 ident: B15 article-title: Tackling the recurrence of Clostridium difficile infection publication-title: Med Mal Infect doi: 10.1016/j.medmal.2017.10.007 – volume: 27 start-page: 2194 year: 2011 end-page: 2200 ident: B44 article-title: UCHIME improves sensitivity and speed of chimera detection publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr381 – volume: 192 start-page: 4904 year: 2010 end-page: 4911 ident: B11 article-title: Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production publication-title: J Bacteriol doi: 10.1128/JB.00445-10 – volume: 1 start-page: 16030 year: 2016 ident: B39 article-title: Getting to know the microbiome publication-title: Nat Microbiol doi: 10.1038/nmicrobiol.2016.30 – volume: 2 start-page: 6 year: 2014 ident: B40 article-title: An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform publication-title: Microbiome doi: 10.1186/2049-2618-2-6 – start-page: 27 year: 2013 end-page: 29 ident: B47 article-title: SUMATRA and SUMACLUST: fast and exact comparison and clustering of sequences publication-title: Programs Abstr SeqBio – volume: 59 start-page: 345 year: 2014 end-page: 354 ident: B23 article-title: Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials publication-title: Clin Infect Dis doi: 10.1093/cid/ciu313 – volume: 23 start-page: 4442 year: 2016 end-page: 4449 ident: B9 article-title: Clostridium difficile infection: associations with chemotherapy, radiation therapy, and targeting therapy treatments publication-title: Curr Med Chem doi: 10.2174/0929867323666161028162018 – volume: 44 start-page: 34 year: 2018 end-page: 40 ident: B35 article-title: Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery publication-title: Curr Opin Microbiol doi: 10.1016/j.mib.2018.07.003 – volume: 29 start-page: 546 year: 2016 end-page: 554 ident: B14 article-title: New and emerging therapies for Clostridium difficile infection publication-title: Curr Opin Infect Dis doi: 10.1097/QCO.0000000000000320 |
| SSID | ssj0006590 |
| Score | 2.432453 |
| Snippet | CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of
Clostridioides difficile
, inhibiting
C. difficile
toxin production and... CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of , inhibiting toxin production and spore formation. CRS3123 has been... CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and... |
| SourceID | unpaywall pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Administration, Oral Adolescent Adult Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - pharmacokinetics Benzopyrans - administration & dosage Benzopyrans - adverse effects Benzopyrans - pharmacokinetics Clostridioides difficile - drug effects Clostridioides difficile - enzymology Clostridioides difficile - genetics Clostridium Infections - drug therapy Cohort Studies Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Electrocardiography Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Enzyme Inhibitors - pharmacokinetics Experimental Therapeutics Female Gastrointestinal Microbiome - drug effects Healthy Volunteers Humans Male Methionine-tRNA Ligase - antagonists & inhibitors Methionine-tRNA Ligase - genetics Microbial Sensitivity Tests Middle Aged Thiophenes - administration & dosage Thiophenes - adverse effects Thiophenes - pharmacokinetics Young Adult |
| Title | Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31685472 https://journals.asm.org/doi/10.1128/AAC.01395-19 https://www.proquest.com/docview/2312281132 https://pubmed.ncbi.nlm.nih.gov/PMC7187627 https://aac.asm.org/content/aac/64/1/e01395-19.full.pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 64 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1098-6596 dateEnd: 20250501 omitProxy: true ssIdentifier: ssj0006590 issn: 0066-4804 databaseCode: HH5 dateStart: 19720101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1098-6596 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006590 issn: 0066-4804 databaseCode: KQ8 dateStart: 19720101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1098-6596 dateEnd: 20250501 omitProxy: true ssIdentifier: ssj0006590 issn: 0066-4804 databaseCode: DIK dateStart: 19720101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1098-6596 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006590 issn: 0066-4804 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1098-6596 dateEnd: 20241101 omitProxy: true ssIdentifier: ssj0006590 issn: 0066-4804 databaseCode: RPM dateStart: 19720101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdYJz5e-CgwysdkEPSFuW2c78eoY0ygVoV2UvcU2YmjTUvTakmEyv_F_8edk2aUahLiJVKSy9lRLr7f2effEfLeHSgz9izOwFwSCFAiwWQiFZMudNu2APALnBoYjZ3TM-vL3J7XUxe4F0aAFpEv9Bo-JmvDyIvX-o7VN_oK8YrNDL-Hc9O9VZzskX3HBhDeIvtn40lwrsddx2GWpwsHQmwDwRH3qjR732MovEl_555ubaMTxmRomG_7px3QuZs7eb_MVmL9Q6TpH47p5BGZb16pyke56pWF7EU__2J7_I93fkwe1mCVBpV1PSF3VNYmd6vyles2uTeqF-bbpDupKLDXR3R2s6MrP6JdOrkhx14_Jb9GdQYjC5BHCj0nO17mCsXgaNCaqDSlmOG4psuEAkSlU5GoApUvU9CuE3rhTGRxo_4K-oFN4hPD71MTfCUI0LEmmWRT3FB6XS5ogFvJKM4-0xE0tICGji_z61KPnPjsGEF8Sj-XBQhULFWFeEZmJ59mw1NWl45gwjK8ggHIUonrS-5byh9IiNq4H7tmPIgB4pmuFHZiubajIkBPXAAkhECZe3HkJ1ICBDKfk1a2zNQLQgFSKXDytuR2bEFsK2wfzk0n8R1DmpHXIe_QbML6189DHVVxLwyCYai_XWj4HfJxY1RhVHOvYwmQ9BbpD430quIcuUXu7cY-QxgUcKVHZGpZ5iGAds49wzB5hxxU9tpowkpltuXCHXfLkhsBJBzfvpNdXmjiccAx4DvdDuk2Nr_TQTDcpoMv_1XwFXkAQFTX5eCD16QFBqHeANgr5CHZ-_rNO6x_799ERk3F |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELegEx8vfBTYypcMgr5sbhvn-zHqGBNSq4p2UnmK7MQR09KkWhKh8n_x_3HnpBmlmoR4iZTkcnaUi-939vl3hHxwR8qMPYszMJcEApRIMJlIxaQL3bYtAPwCpwYmU-f8wvqytJfN1AXuhRGgRRQrvYaPydow8uK1oWMNjaFCvGIzwx_g3PRgHSd3yYFjAwjvkIOL6Sz4psddx2GWpwsHQmwDwRH36jR732MovE1_555ubasTxmRomO_6pz3QuZ87-aDK1mLzQ6TpH47p7DFZbl-pzke5GlSlHEQ__2J7_I93fkIeNWCVBrV1PSV3VNYl9-rylZsuuT9pFua7pD-rKbA3J3Rxs6OrOKF9Orshx948I78mTQYjC5BHCj0nO80LhWJwNGhDVJpSzHDc0DyhAFHpXCSqROV5Ctp1Qi-ciSxu1V9BP7BJfGL8dW6CrwQBOtUkk2yOG0qvqxUNcCsZxdlnOoGGVtDQ6WVxXemRE5-dIohP6eeqBIGapaoUz8ni7NNifM6a0hFMWIZXMgBZKnF9yX1L-SMJURv3Y9eMRzFAPNOVwk4s13ZUBOiJC4CEEChzL478REqAQOYL0snyTB0RCpBKgZO3JbdjC2JbYftwbjqJ7xjSjLweeY9mEza_fhHqqIp7YRCMQ_3tQsPvkeOtUYVRw72OJUDSW6Q_ttLrmnPkFrl3W_sMYVDAlR6RqbwqQgDtnHuGYfIeOazttdWElcpsy4U77o4ltwJIOL57J7v8ronHAceA73R7pN_a_F4HwXDbDr78V8FX5CEAUV2Xg49ekw4YhHoDYK-Ub5sf-zd3RUzQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multiple-Ascending-Dose+Phase+1+Clinical+Study+of+the+Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+CRS3123%2C+a+Narrow-Spectrum+Agent+with+Minimal+Disruption+of+Normal+Gut+Microbiota&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Lomeli%2C+Barbara+K.&rft.au=Galbraith%2C+Hal&rft.au=Schettler%2C+Jared&rft.au=Saviolakis%2C+George+A.&rft.date=2019-12-20&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=64&rft.issue=1&rft_id=info:doi/10.1128%2FAAC.01395-19&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_AAC_01395_19 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |